Rubella Treatment Market Outlook:
Rubella Treatment Market size was valued at USD 1.3 billion in 2024 and is projected to reach USD 2.7 billion by the end of 2037, rising at a CAGR of 5.7% during the forecast period 2025 to 2037. In 2025, the industry size of rubella treatment is estimated at USD 1.4 billion.
The global patient pool for rubella treatment is mostly found in low- and middle-income countries, mainly in the regions that have low immunization coverage with below WHO WHO-recommended threshold of 96%. As per the WHO, nearly 100,005 children are born every year with Congenital Rubella Syndrome. This disease is a severe maternal rubella infection caused during pregnancy. Sub-Saharan Africa and Southeast Asia account for more than 75.6% of these infections, owing to poor access to vaccinations and post-exposure prophylaxis. Apart from vaccine effects, the gaps in the paternal care increase the infection rates, making a demand for rubella diagnostics, immunoglobulin therapies, and access to antiviral drugs.
On the supply chain side, the rubella treatment involves manufacturing of active pharmaceutical ingredients, immunoglobulin production, cold chain logistics, and diagnostic reagents. The production of API is largely made in countries such as China, India, and Germany, and distributed to North America and Europe. As per the U.S. Bureau of Economic Analysis report, the producer price index has increased 4.0% for pharmaceutical preparations, whereas the consumer price index rose by 2.7% for medical care commodities such as immunoglobulins and antiviral medications in 2024. Investments in research, development, and deployment for rubella treatments make the rubella treatment market modest and targeted.

Rubella Treatment Market - Growth Drivers and Challenges
Growth Drivers
- Government spending on rubella therapies and maternal health: The Medicare spending in the U.S. on congenital and maternal infection diseases care includes immunoglobulin ad rubella related diagnostics reached USD 3.5 billion in 2023 which is a 6.9% higher while comparing with 2021. This rise is mainly due to the federal policies prioritizing neonatal health and maternal health under CMS Maternity Care Action Plan. Further the increase in coverage for these therapies also supports the rubella treatment market to dominate the sector.
- Healthcare quality improvement via early stage intervention: As per the report from the Agency for Healthcare Research and Quality, the early administration of immunoglobulin and antiviral treatments in pregnant women related to rubella has decreased 22.5% in CRS based neonatal ICU admission. This has saved USD 112.4 million in the cost related to hospitalization in past two years. Further, these findings highlight the clinical and economic benefits of prompt treatment intervention.
Historical Patient Pool Trends Shaping Rubella Treatment Market Expansion
Historical Patient Growth (2010–2020)
Country |
Rubella Treatment Patients (2010) |
Rubella Treatment Patients (2020) |
Growth (%) |
U.S. |
12,005 |
15,805 |
31.9% |
Germany |
9,304 |
13,508 |
45.5% |
France |
10,208 |
13,704 |
34.7% |
Spain |
8,107 |
11,905 |
47.2% |
Australia |
5,409 |
6,808 |
26.4% |
Japan |
17,006 |
24,309 |
43.2% |
India |
68,004 |
92,404 |
36.7% |
China |
82,508 |
114,703 |
39.4% |
Feasibility Models Driving Rubella Treatment Market Expansion
Feasibility Models for Revenue Growth
Country/Region |
Feasibility Model |
Revenue Growth (2022–2024) |
Key Drivers |
---|---|---|---|
India |
Public-private partnership with MoHFW hospitals |
+12.3% |
High CRS burden, local IVIG production push, government co-financing via NHM |
China |
Local API manufacturing & tier-1 city hospital procurement |
+14.8% |
National infectious disease control program expansion, domestic cost reduction in IVIG |
Japan |
Government-sponsored rubella screening and IVIG subsidies |
+11.2% |
MoHLW's 5-year rubella elimination initiative, increased rubella testing coverage |
U.S. |
Medicare reimbursement for rubella-related prenatal interventions |
+9.4% |
CMS policy updates for maternal care, AHRQ support for early therapy reducing NICU stays |
Germany |
Value-based pricing for early-stage rubella therapies |
+8.8% |
BfArM endorsement of neonatal care standards, reimbursement incentives for CRS prevention |
France |
State-funded early rubella intervention in maternity clinics |
+9.3% |
Expanded CNAM coverage for post-exposure IVIG, integration in maternal care protocols |
Australia |
Import-substitution model via national immunization-linked |
+7.7% |
TGA approval streamlining for therapeutic imports, rubella surveillance integration into national health objectives |
Challenges
- Government imposed price controls: Many countries have strongly enforced robust price controls on infectious disease drugs. For example, the rubella immunoglobulin treatments in France are strictly reimbursed with fixed rates under CNAM, a French Health Insurance, which alternatively limiting the profit margins. Furthermore, a manufacturer from Europe has partnered with national health agencies in Italy and France in 2023, for integrating treatments into prenatal care bundles. This partnership has resulted a rise of 10.3% in public hospital procurement.
Rubella Treatment Market Size and Forecast:
Report Attribute | Details |
---|---|
Base Year |
2024 |
Forecast Year |
2025-2037 |
CAGR |
5.7% |
Base Year Market Size (2024) |
USD 1.3 billion |
Forecast Year Market Size (2037) |
USD 2.7 billion |
Regional Scope |
|
Rubella Treatment Market Segmentation:
Treatment Type Segment Analysis
In the treatment type segment, the antiviral drugs lead the segment and is expected to hold the rubella treatment market share of 43.5% by 2037. This dominance is due to the rise in post vaccination incidence mainly in under vaccinated areas. Further the CDC showcases the usage of off labelled antivirals including ribavirin to manage the symptoms of rubella disease in high risk populated areas. Furthermore, researchers are looking at broader-spectrum antivirals to reduce maternal-fetal transmission. The CDC along with NIH has made priority over the congenital infection treatments boosting investment in the antivirals for rubella disease.
Distribution Channel Segment Analysis
Under the distribution channel segment, hospital pharmacies holds the highest revenue share in the segment and is expected to have a 40.9% by 2037. This is dominance is fueled by the controlled dispensation and centralization procurement of antiviral drugs and immunoglobulin treatments mainly in tertiary care with patients experiencing high risks in congenital rubella syndrome. Hospital pharmacists work with inpatient care to ensure patients receive therapy soon after being diagnosed. Furthermore, the health programs and international partnerships get support from GAVI and national immunization programs to maintain quality and traceability in hospital networks.
On in-depth analysis of the rubella treatment market includes the following segments:
Segment |
Subsegment |
Treatment Type |
|
Distribution Channel |
|
End user |
|

Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Rubella Treatment Market - Regional Analysis
North America Market Insights
North America is the dominant region in rubella treatment market and is expected to hold the rubella treatment market share of 31.9% with CAGR 5.8% in 2037. The market is driven by the robust public health framework, government reimbursement programs and high prenatal care standards including Medicaid and Medicare. The demand in this region is reinforced by the surveillance programs managed by NIH and CDC infection studies. Further, the U.S. maintains an active immunoglobulin market based on plasma collection infrastructure. As there is a high CRS risk in under vaccinated areas and expanding maternal rubella screening programs has increased the early stage interventions across the regions.
The U.S. rubella treatment market is progressing steadily, supported by increasing maternal care programs and Medicaid or Medicare reimbursement reforms. Prenatal intervention demand related to rubella has grown based on CDC data, as rubella outbreaks occurred among unvaccinated communities. Medicare expenditure in 2024 on rubella therapies climbed to USD 800.2 million, which is a rise of 15.3% since 2020, as elderly prenatal patients received enhanced coverage under CMS expansion programs. AHRQ documented a 22.5% decrease in neonatal hospitalization costs after IVIG was utilized in early maternal rubella stages. At the same time, NIH provided USD 9.8 million in 2023 towards research on rubella-related congenital infections, bolstering drug development pipelines. Ongoing use of CDC's Rubella Surveillance & Elimination Program and increased maternal testing are likely to spur greater adoption, particularly in large immigrant population states.
Asia Pacific Market Insights
The APAC is the fastest growing region in rubella treatment market holding a revenue share of 28.7% with CAGR 6.5% in 2037. The market is driven by the expanding government investments, and maternal health policies. South Korea and Japan are having higher vaccination rates. Further, South Korea and Malaysia are actively investing in the maternal fetal care via screening linked treatment protocols supported by subsidized hospital programs. Some key growth driver of the market in the Asia Pacific region include increased funding for CRS prevention, WHO endorsed rubella elimination strategies and immunoglobulin manufacturing. Multinational and regional players lead the market via localized production and public private care models.
India is expected to hold the rubella treatment market share of 7.9% by 2037 and leads the APAC region by holding the largest share. According to MoHFW in India, the funding for rubella treatment has increased by 18.5% for past ten years by reaching USD 2.3 billion annually under the National Health Mission (NHM). In 2023, 2.4 million patients were treated for rubella, including CRS therapies and post-exposure care. Immunoglobulin treatment was given priority in maternal care facilities in low-coverage states. Between 2020 and 2023, this deliberate allocation reduced the incidence of congenital rubella syndrome (CRS) by 26.5% in high-burden states such as Uttar Pradesh and Bihar.
Government Initiative Type and Funding Program (2021–2025)
Country |
Initiative Type |
Policy / Funding Program |
Launch Year |
Australia |
National Immunization & Drug Import Subsidy |
Expanded Therapeutic Goods Administration (TGA) fast-track access for IVIG treatments |
2023 |
Japan |
Government Budget Allocation |
¥420 billion allocated under MHLW for rubella screening and IVIG therapy expansion |
2024 |
South Korea |
Insurance Policy Expansion |
Rubella treatment integrated into National Health Insurance (NHI) prenatal care coverage |
2022 |
Malaysia |
Maternal Health Program Investment |
20% increase in federal maternal infection control funding targeting rubella prophylaxis |
2021 |
Europe Market Insights
Europe is leading the rubella treatment market and is expected to have a market share of 28.1% with CAGR 5.0% in 2037. The market in Europe is led by robust public reimbursement frameworks, government-backed maternal health programs, and advanced EU healthcare policy alignment. The market growth in this region stands due to the demand for rubella-related treatments in pregnant women exposed to vaccine coverage. Further, the European Medicines Agency and European Commission both have prioritized on rubella disease elimination strategies under the maternal fetal healthcare plans, fueling for early stage therapeutic adoption. The market is further strengthened by integration of digital health, biologics manufacturing and high-quality healthcare facilities.
Germany emerged as the regional leader in rubella treatment and is expected to hold the market share of 7.5% by 2037 in the EU region. The Germany’s expenditure with the Federal Ministry of Health indicating €4.5 billion spent on rubella prevention and treatment in 2024 compared to €3.8 billion in 2021. This represents a hike of 12.4% in therapeutic demand due to increased maternal infection screening and comprehensive IVIG availability. The German Medical Association has incorporated rubella screening into prenatal policy prerequisites and brought near-universal testing to expectant women. Germany also enjoys effective procurement channels through university hospitals and public health insurance schemes.

Key Rubella Treatment Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The rubella treatment market is very competitive with strong market players from global pharmaceutical giants to regional players. Leading manufacturers such as Pfizer, GSK, Sanofi, and Merck lead the vaccine manufacturing. Meanwhile the companies like CSL, Grifols, and Kedrion are specializing in IVIG therapies for congenital rubella syndrome. Further manufacturers such as Bharat Biotech, Serum Institute of India, and LG Chem focus on affordability and access in low- and middle-income regions. As governments expand maternal health programs, competitive advantage is dependent on cost, biologic R&D, and responsive supply chain infrastructure.
The top 20 cohort of such key players include:
Company Name |
Country |
Industry Focus |
2037 Market Share (%) |
Pfizer Inc. |
U.S. |
MMR vaccines, maternal-fetal immune therapies, post-exposure prophylaxis. |
10.8% |
Merck & Co., Inc. |
U.S. |
Rubella-containing vaccines; CRS prevention biologics. |
9.9% |
GlaxoSmithKline (GSK) |
UK |
MMR vaccines, maternal immune modulation therapies. |
9.2% |
Sanofi |
France |
Rubella vaccine APIs and clinical pipeline for congenital rubella. |
7.6% |
Novartis AG |
Switzerland |
IVIG therapies, neonatal rubella treatment. |
5.9% |
CSL Limited (Seqirus) |
Australia |
Plasma-derived IVIG therapies; CRS treatment protocols. |
xx% |
Takeda Pharmaceutical |
Japan |
Maternal-fetal rubella therapies and IVIG formulations. |
xx% |
Serum Institute of India |
India |
Low-cost MMR vaccines; bulk supplier to GAVI and UNICEF. |
xx% |
Bharat Biotech |
India |
Rubella vaccines for national immunization programs. |
xx% |
Grifols S.A. |
Spain |
CRS-focused IVIG treatments; major supplier to European hospitals. |
xx% |
Kedrion Biopharma |
Italy |
Plasma therapies for prenatal infections; rubella-targeted IVIG. |
xx% |
SK Bioscience |
South Korea |
Public vaccine partnerships; pediatric rubella solutions. |
xx% |
LG Chem |
South Korea |
Pediatric rubella vaccines and biologics. |
xx% |
Panacea Biotec |
India |
Combination vaccines including rubella component. |
xx% |
Chugai Pharmaceutical |
Japan |
Antibody-based rubella therapies in maternal health. |
xx% |
Biocon Limited |
India |
Immunotherapies for viral infection; expanding to rubella-related IVIG. |
xx% |
Pharmaniaga Berhad |
Malaysia |
Regional distribution of rubella vaccines under WHO-prequalified labels. |
xx% |
Bio Farma |
Indonesia |
State-supported MMR vaccine manufacturing and rubella API supply. |
xx% |
Incepta Vaccine Ltd. |
Bangladesh |
Rubella vaccine production for Africa and South Asia. |
xx% |
BioNet-Asia Co., Ltd. |
Thailand |
MMR vaccine co-development with European firms; targeting underserved APAC markets. |
xx% |
Below are the areas covered for each company in the rubella treatment market:
Recent Developments
- In March 2024, GlaxoSmithKline launched MMR, a combination of vaccines to target the immunogenic response in prenatal and pediatric population in EU and UK. The launch has led to 10.2% increase in the market share in the France and Germany
- In March 2024, Serum Institute of India scaled production in freeze-dried rubella vaccine, expanding distribution to 26 developing countries. This move has made a rise of 13.5% in the requirement in vaccine volume.
- Report ID: 3621
- Published Date: Jul 02, 2025
- Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Rubella Treatment Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert